Back to Peptides
Skin & JointLow Risk

Cartalax

Also known as: Ala-Glu-Asp-Arg, Cartilage bioregulator, Khavinson cartilage peptide

Half-life:
Unknown

Administration Routes

subcutaneous injectionoral
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

A Khavinson peptide bioregulator targeting cartilage tissue. Promotes chondrocyte activity and cartilage matrix regeneration; studied for osteoarthritis and joint degeneration.

Primary Research Areas

  • cartilage regeneration
  • joint repair
  • chondrocyte function support

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Russian joint/cartilage peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Cartalax

No active associated providers listed yet.